How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup
Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the…
1 article · 1+ outlets
Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the…